Nanobiotix S.A. (EPA:NANO)
France flag France · Delayed Price · Currency is EUR
27.40
-1.55 (-5.35%)
Apr 2, 2026, 5:36 PM CET

Nanobiotix Income Statement

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
29.64-11.6130.06-0.01
Other Revenue
2.954.426.154.782.64
32.59-7.1936.214.782.65
Revenue Growth (YoY)
--658.12%80.43%13.85%
Gross Profit
32.59-7.1936.214.782.65
Selling, General & Admin
20.3620.5322.0517.8619.43
Research & Development
23.1240.5438.432.6430.38
Other Operating Expenses
-0.06----
Operating Expenses
43.4161.0760.4550.4949.81
Operating Income
-10.82-68.26-24.24-45.72-47.17
Interest Expense
-15.23-8.09-7.98-5.84-0.67
Interest & Investment Income
-2.631.220.26-
Currency Exchange Gain (Loss)
-2.99-2.092.116.24
Other Non Operating Income (Expenses)
2.090000.01
EBT Excluding Unusual Items
-23.96-70.73-33.09-49.19-41.58
Gain (Loss) on Sale of Investments
---4.23--
Other Unusual Items
-2.7-2.26-7.84-5.41
Pretax Income
-23.96-68.03-39.58-57.03-47
Income Tax Expense
00.10.120.010.01
Net Income
-23.96-68.13-39.7-57.04-47
Preferred Dividends & Other Adjustments
----0.06
Net Income to Common
-23.96-68.13-39.7-57.04-47.06
Shares Outstanding (Basic)
4847373535
Shares Outstanding (Diluted)
4847373535
Shares Change (YoY)
1.39%27.99%5.96%0.34%42.43%
EPS (Basic)
-0.50-1.44-1.08-1.64-1.35
EPS (Diluted)
-0.50-1.44-1.08-1.64-1.35
Free Cash Flow
-33.96-20.4-12.8-37.2-30.1
Free Cash Flow Per Share
-0.71-0.43-0.35-1.07-0.87
Gross Margin
100.00%-100.00%100.00%100.00%
Operating Margin
-33.19%--66.94%-957.22%-1781.83%
Profit Margin
-73.52%--109.64%-1194.33%-1777.97%
Free Cash Flow Margin
-104.19%--35.36%-778.79%-1137.14%
EBITDA
-9.32-67.67-23.69-44.22-45.61
EBITDA Margin
-28.60%--65.42%--
D&A For EBITDA
1.50.590.551.51.56
EBIT
-10.82-68.26-24.24-45.72-47.17
EBIT Margin
-33.19%--66.94%--
Revenue as Reported
32.59-7.1936.214.782.65
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.